Bonus BioGroup is developing an innovative tissue engineering technology to produce cell-based therapies:

BonoFill^TM: A personalized, viable bone graft for bone tissue repair that is specifically tailored to the biological, physical and clinical needs of each patient.

MesenCure: Bonus BioGroup has joined the global efforts to fight the novel coronavirus (COVID-19) pandemic outbreak, and is currently developing an advanced, cell therapy for the attenuation of the life-threatening acute respiratory distress in COVID-19 pneumonia.